-
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
25 Apr 2024 03:36 GMT
… Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: June 3 …
-
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
24 Apr 2024 20:16 GMT
… Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Session Date and … Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Session Date and … Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Session Date and …
-
Combination therapy lowers blood pressure in patients receiving ibrutinib, reveals study
24 Apr 2024 20:47 GMT
… patients with mantle cell lymphoma, chronic lymphocytic leukemia, and certain other lymphoid cancers …
-
Long-Term, Real-World Data Support Ibrutinib Efficacy, Safety in CLL
24 Apr 2024 17:34 GMT
… treatment option for patients with chronic lymphocytic leukemia (CLL). The EVIdeNCE data, from … ibrutinib in Italian patients with chronic lymphocytic leukemia: final results of the EVIdeNCE …
-
Review Chronicles Advancing Insights Into Epigenetic Alterations in Chronic Lymphocytic Leukemia
30 Mar 2024 16:53 GMT
… mechanisms and targeted therapies for chronic lymphocytic leukemia (CLL) have led to better … . Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment. Clin …
-
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
27 Mar 2024 22:18 GMT
Ibrutinib (IMBRUVICA®), has revolutionized the treatment of the B cell malignancy, CLL [1]. Ibrutinib is a covalent active site inhibitor of the multi-domain B-cell kinase, BTK (Fig. 1a), that was first approved by the FDA in 2013 [2]. Inhibition of BTK …
-
FDA Drug Approvals Q1 2024
24 Apr 2024 15:11 GMT
… adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma …
-
Venetoclax monotherapy effectively treats relapsed or refractory chronic lymphocytic leukemia
26 Mar 2024 14:18 GMT
… treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). Patients included either previously … patients with relapsed or refractory chronic lymphocytic leukemia, including those who have received …
-
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
24 Apr 2024 14:05 GMT
… Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Birhiray, R.
Monday … Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Matasar, M.
… Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Luminari, S.
…
-
FDA approves Breyanzi CAR-T for chronic lymphocytic leukemia, small lymphocytic lymphoma
15 Mar 2024 15:41 GMT
… patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The … patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Image …